Alphabiome AI

Alphabiome AI Overview

Alphabiome uses artificial intelligence to decode the genetic complexity of the human microbiome and identify biomarkers that predict treatment efficacy. Alphabiome’s mission is to unlock the full potential of the microbiome to transform how diseases are understood, diagnosed, and treated . Its proprietary technology enables large-scale, reference-free analysis of microbial DNA – converting trillions of untapped genetic fragments into actionable insights for drug development, clinical decision-making, and precision medicine.

Cumulative Funding Raised Over Time ($)

Latest News

May 6, 2025 · www.finsmes.com

growth-positive

Alphabiome Raises $8M in Seed Funding

Alphabiome, based in Tel Aviv, Israel, has secured $8 million in Seed funding led by AIX Ventures. The company specializes in extracting genetic biomarkers from microbial DNA using a proprietary AI model. The funding will be used to expand operations and enhance R&D efforts. Alphabiomes approach combines AI and microbiome analytics to identify microbial DNA patterns, which can predict drug efficacy and advance precision medicine. Recently, the company conducted a trial involving Ulcerative Colitis and Crohn’s patients, identifying over 10,000 biomarkers related to drug use. This advancement highlights the potential of Alphabiomes technology in precision medicine.

InvestmentProduct Stage

Funding

Team Members

6

Employees: 1-10

Web & Social Links

Locations

Tel Aviv-Yafo, Israel

Cambridge, MA, USA

Photos & Videos

1 item(s)

Alphabiome AI Internal

Recent Updates

No update log entries.

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info